Bitget App
Trade smarter
MarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Market Movement: Flex plummets on October 22—target price lowered, split financing risks, continued decline

US Stock Market Movement: Flex plummets on October 22—target price lowered, split financing risks, continued decline

Bitget异动解读Bitget异动解读2026/10/22 13:51
Show original

Flextronics October 22 Sharp Decline Interpretation

Keywords: Target Price Downgrade, Spin-off Financing Risk, Ongoing Decline

1. On October 19, Baird lowered the target price of Flextronics from $142 to $135, maintaining a Buy rating. The downward revision of the target price reflects a decrease in the analyst’s valuation expectations.

2. On October 5, the company disclosed that the EPC Power acquisition would result in $4.4 billion in short-term debt, with repayment arrangements depending on the spin-off and related financing. If the spin-off is delayed or not completed, the company may need to repay or refinance the debt separately.

3. On October 22, the share price fell for the eighth consecutive trading day, indicating a continued short-term downward trend.

(Disclaimer: This content is generated by AI technology, summarizing publicly available information for reference only and does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations

Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.

华尔街见闻•2026/10/22 21:01